RxDoctor Payments Data

Satish Mital, MD

Internal Medicine · Tallahassee, FLNPI 1497740740

Payments from drug & device makers

$367in general payments, 2019–2025

Across 17 payments — averaging $21.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dexcom, Inc.$78
  • E.r. Squibb & Sons, L.L.C.$75
  • Pfizer$55
  • Novo Nordisk$53
  • Bolton Medical Inc$33
  • Merck$22
  • plus $52 from 4 others

What the payments were for

  • Food & beverage$33491%
  • Education$339%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$367 in reported general payments places this provider in the 50th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$249,126
Medicare patients
452
Services billed
4,280

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban242$215,984
JardianceEmpagliflozin142$135,815
OzempicSemaglutide84$110,723
JanuviaSitagliptin Phosphate85$85,468
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$27,600
FarxigaDapagliflozin Propanediol31$26,813
XareltoRivaroxaban24$26,339
TrulicityDulaglutide12$12,172
MyrbetriqMirabegron16$11,917
Breo ElliptaFluticasone/Vilanterol20$10,658
Rosuvastatin Calcium672$10,227
Repatha SureclickEvolocumab14$8,807
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog11$7,890
Levothyroxine Sodium432$6,428
SynthroidLevothyroxine Sodium55$5,847

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$55$215,984242 claims
Novo NordiskOzempic$53$110,72384 claims
MerckJanuvia$22$85,46885 claims
AstraZenecaFarxiga$16$26,81331 claims
Lilly USA, LLCTrulicity$12$12,17212 claims
Astellas Pharma US IncMyrbetriq$3$11,91716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Tallahassee

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →